G1 Therapeutics to Present at H.C. Wainwright Investment Conference on September 5, 2018

August 28, 2018

RESEARCH TRIANGLE PARK, N.C., Aug. 28, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Buck Phillips, Chief Financial Officer and Senior Vice President, Corporate Development will present a company overview at the following investor conference:

- H.C. Wainwright 20th Annual Global Investment Conference: Wednesday, September 5 at 9:10 a.m. ET at the St. Regis Hotel in New York, NY.

A live and archived webcast of the presentation will be available on the [Events & Presentations](#) page of the company's website: [www.g1therapeutics.com](#).

About G1 Therapeutics
G1 Therapeutics, Inc. (G1) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company's pipeline assets, trilaciclib and lerociclib, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and lerociclib have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. Lerociclib is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted therapies. G1 is also advancing G1T48, a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer.

G1 is based in Research Triangle Park, NC. For additional information, please visit [www.g1therapeutics.com](#) and follow us on Twitter @G1Therapeutics.

Contact:
Jeff Macdonald
Head of Investor Relations / Public Relations
917-371-0940
[jmacdonald@g1therapeutics.com](#)

G1 Therapeutics